PARD3, par-3 family cell polarity regulator, 56288

N. diseases: 68; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C3891448
Disease: NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO
NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO 		0.400 CausalMutation disease CLINVAR Rare Deleterious PARD3 Variants in the aPKC-Binding Region are Implicated in the Pathogenesis of Human Cranial Neural Tube Defects Via Disrupting Apical Tight Junction Formation. 27925688 2017
CUI: C3891448
Disease: NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO
NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO 		0.400 SusceptibilityMutation disease CLINVAR Rare Deleterious PARD3 Variants in the aPKC-Binding Region are Implicated in the Pathogenesis of Human Cranial Neural Tube Defects Via Disrupting Apical Tight Junction Formation. 27925688 2017
CUI: C3891448
Disease: NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO
NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO 		0.400 GeneticVariation disease UNIPROT Rare Deleterious PARD3 Variants in the aPKC-Binding Region are Implicated in the Pathogenesis of Human Cranial Neural Tube Defects Via Disrupting Apical Tight Junction Formation. 27925688 2017
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.320 Biomarker disease CTD_human We validated ZBTB20, CELF2, PARD3, AKAP13 and WAC, which were identified by our screens in multiple cancer types, as new tumor suppressor genes in prostate cancer. 28319090 2017
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.320 Biomarker disease BEFREE Knockdown of Par3 inhibits PCa cell migration and invasion in vitro and tumor metastasis in vivo, whereas overexpression of Par3 yields the opposite results. 29017577 2017
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.320 AlteredExpression disease BEFREE The mutational inactivation in a prostate cancer cell line of the PARD3 gene involved in asymmetric cell division and maintenance of cell-polarity suggests that the loss of cell-polarity contributes to prostate carcinogenesis. 19737411 2009
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.310 GeneticVariation group BEFREE Interestingly, co-deletion of Par3 and Lats1 for complete blockade of the Hippo pathway in mice results in prostate tumor initiation, whereas co-deletion of Par3 and YAP for disrupting YAP nuclear translocation reverses the phenotypes to a relatively normal state. 30467379 2019
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.310 Biomarker group CTD_human A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes. 28319090 2017
CUI: C0005890
Disease: Body Height
Body Height 		0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0042834
Disease: Vital capacity
Vital capacity 		0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C1305855
Disease: Body mass index
Body mass index 		0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0596887
Disease: mathematical ability
mathematical ability 		0.100 GeneticVariation phenotype GWASCAT Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. 30038396 2018
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.090 AlteredExpression phenotype BEFREE The expression of Pard3 was increased by the inhibition of miR-483, but TGF-β1-induced cell migration and invasion were decreased by miR-483 inhibition. 30171257 2019
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.090 Biomarker phenotype BEFREE Epidermal loss of Par3, aPKCλ, or both, strongly reduced tumor multiplicity and increased latency but inhibited invasion to similar extents, indicating that Par3 and aPKCλ function as a complex to promote tumorigenesis. 29789715 2018
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.090 Biomarker phenotype BEFREE Diminished expression of ASPP2 and loss of junctional PAR3 localization were significantly associated with diffuse-type histology, deeper invasion depth, positive peritoneal dissemination and worse prognosis in primary GC. 28400336 2017
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.090 AlteredExpression phenotype BEFREE Overexpression of PARD3 exerted its antitumor activity in vitro by impairing cell proliferation, inducing apoptosis, and inhibiting migration and invasion of Eca109 cells, suggesting that PARD3 might play a tumor suppressor role in ESCC. 28526815 2017
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.090 Biomarker phenotype BEFREE Knockdown of Par3 inhibits PCa cell migration and invasion in vitro and tumor metastasis in vivo, whereas overexpression of Par3 yields the opposite results. 29017577 2017
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.090 AlteredExpression phenotype BEFREE Negative PAR-3 protein expression, but not negative ZO-1 or claudin-1 expression, was significantly associated with deeper tumor invasion (P<.01), positive lymph node metastasis (P=.03), and advanced tumor stage (P=.01). 28188749 2017
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.090 Biomarker phenotype BEFREE Overall, we show that Gα13 and DDR1-Par3 differentially regulate cell-cell junctions and the actin cytoskeleton to mediate invasion in three-dimensional collagen. 26589794 2016
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.090 Biomarker phenotype BEFREE Stimulation of PAR-1 or PAR-2 by their peptide agonists increased, whereas PAR-3 agonist reduced the invasion of the control cells. 23921961 2014
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.090 Biomarker phenotype BEFREE Par3 depletion was associated with induction of MMP9, destruction of the extracellular matrix, and invasion, all mediated by atypical PKC-dependant JAK/Stat3 activation. 23153534 2012
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.080 Biomarker phenotype BEFREE By restoration assessment, we found that only re-expression of a fully functional Gab1, but not a mutant Gab1 that harbors either Par3 binding-deficiency or Par1b binding-deficiency, could reverse the repressive phenotype of cell migration in vitro and metastasis in vivo due to Gab1 knockdown. 30665442 2019
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.080 Biomarker phenotype BEFREE Therefore, our findings highlight combination of Par3 loss and blockade of the Hippo pathway as a novel mechanism for prostatic tumorigenesis. 30467379 2019
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.080 Biomarker phenotype BEFREE In the inflammatory tumorigenesis phase Par3/aPKCλ cooperate to drive Stat3 activation and hyperproliferation. 29789715 2018
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.080 Biomarker phenotype BEFREE Par3, Par6β, and protein kinase Cζ (PKCζ), which are PAR complex members, have been shown to be associated with oncogenesis and progression. 29220829 2018